MedTrace Logo

A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)

NCT01673620 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2024-09-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability of montelukast 10 mg/loratadine 10 mg versus placebo in Mexican participants with allergic rhinitis.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Montelukast 10 mg/loratadine 10 mg

Montelukast 10 mg/loratadine 10 mg tablet administered once daily

DRUG

Placebo

Matching placebo tablet administered once daily

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-04
Primary Completion
2012-10-10
Completion
2012-10-10

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673620 on ClinicalTrials.gov